Annual Total Liabilities:
$775.17M+$70.91M(+10.07%)Summary
- As of today, PCRX annual total liabilities is $775.17 million, with the most recent change of +$70.91 million (+10.07%) on December 31, 2024.
- During the last 3 years, PCRX annual total liabilities has fallen by -$569.78 million (-42.36%).
- PCRX annual total liabilities is now -42.36% below its all-time high of $1.34 billion, reached on December 31, 2021.
Performance
PCRX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Total Liabilities:
$570.36M-$209.13M(-26.83%)Summary
- As of today, PCRX quarterly total liabilities is $570.36 million, with the most recent change of -$209.13 million (-26.83%) on September 30, 2025.
- Over the past year, PCRX quarterly total liabilities has dropped by -$201.75 million (-26.13%).
- PCRX quarterly total liabilities is now -57.59% below its all-time high of $1.34 billion, reached on December 31, 2021.
Performance
PCRX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
PCRX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +10.1% | -26.1% |
| 3Y3 Years | -42.4% | -40.9% |
| 5Y5 Years | +62.8% | -10.3% |
PCRX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -42.4% | +10.1% | -40.9% | at low |
| 5Y | 5-Year | -42.4% | +62.8% | -57.6% | at low |
| All-Time | All-Time | -42.4% | +1700.6% | -57.6% | +1134.6% |
PCRX Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $570.36M(-26.8%) |
| Jun 2025 | - | $779.50M(-1.1%) |
| Mar 2025 | - | $788.13M(+1.7%) |
| Dec 2024 | $775.17M(+10.1%) | $775.17M(+0.4%) |
| Sep 2024 | - | $772.11M(+0.6%) |
| Jun 2024 | - | $767.54M(+11.1%) |
| Mar 2024 | - | $691.16M(-1.9%) |
| Dec 2023 | $704.26M(-22.3%) | $704.26M(+0.2%) |
| Sep 2023 | - | $702.91M(-4.3%) |
| Jun 2023 | - | $734.41M(-2.8%) |
| Mar 2023 | - | $755.38M(-16.6%) |
| Dec 2022 | $906.19M(-32.6%) | $906.19M(-6.0%) |
| Sep 2022 | - | $964.24M(-1.3%) |
| Jun 2022 | - | $977.35M(-17.3%) |
| Mar 2022 | - | $1.18B(-12.1%) |
| Dec 2021 | $1.34B(+105.4%) | $1.34B(+111.0%) |
| Sep 2021 | - | $637.40M(-0.2%) |
| Jun 2021 | - | $638.66M(+0.3%) |
| Mar 2021 | - | $636.73M(-2.8%) |
| Dec 2020 | $654.83M(+37.5%) | $654.83M(+3.0%) |
| Sep 2020 | - | $635.58M(+33.0%) |
| Jun 2020 | - | $477.96M(+6.8%) |
| Mar 2020 | - | $447.34M(-6.0%) |
| Dec 2019 | $476.12M(+29.3%) | $476.12M(+3.2%) |
| Sep 2019 | - | $461.33M(+3.4%) |
| Jun 2019 | - | $446.19M(+13.9%) |
| Mar 2019 | - | $391.64M(+6.4%) |
| Dec 2018 | $368.13M(+5.5%) | $368.13M(+2.9%) |
| Sep 2018 | - | $357.78M(+1.6%) |
| Jun 2018 | - | $352.17M(+2.5%) |
| Mar 2018 | - | $343.52M(-1.5%) |
| Dec 2017 | $348.89M | $348.89M(+2.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $341.29M(-1.0%) |
| Jun 2017 | - | $344.70M(+4.7%) |
| Mar 2017 | - | $329.33M(+90.9%) |
| Dec 2016 | $172.49M(+1.9%) | $172.49M(+3.3%) |
| Sep 2016 | - | $167.00M(-3.1%) |
| Jun 2016 | - | $172.35M(+4.4%) |
| Mar 2016 | - | $165.04M(+3.2%) |
| Dec 2015 | $169.34M(+9.3%) | - |
| Sep 2015 | - | $159.97M(+0.2%) |
| Jun 2015 | - | $159.71M(+5.8%) |
| Mar 2015 | - | $151.01M(-2.5%) |
| Dec 2014 | $154.93M(+20.5%) | $154.93M(+3.1%) |
| Sep 2014 | - | $150.32M(+4.3%) |
| Jun 2014 | - | $144.11M(+12.6%) |
| Mar 2014 | - | $127.98M(-0.5%) |
| Dec 2013 | $128.57M(+178.3%) | $128.57M(+4.3%) |
| Sep 2013 | - | $123.28M(+3.3%) |
| Jun 2013 | - | $119.29M(+3.3%) |
| Mar 2013 | - | $115.45M(+149.9%) |
| Dec 2012 | $46.20M(-29.2%) | $46.20M(-11.8%) |
| Sep 2012 | - | $52.38M(+8.3%) |
| Jun 2012 | - | $48.35M(-15.2%) |
| Mar 2012 | - | $57.02M(-12.6%) |
| Dec 2011 | $65.22M(-43.3%) | $65.22M(+2.3%) |
| Sep 2011 | - | $63.73M(-0.7%) |
| Jun 2011 | - | $64.16M(-3.8%) |
| Mar 2011 | - | $66.72M(-42.0%) |
| Dec 2010 | $114.94M(+71.8%) | $114.94M(+68.7%) |
| Sep 2010 | - | $68.14M(-19.3%) |
| Jun 2010 | - | $84.47M(+26.3%) |
| Dec 2009 | $66.90M(+55.4%) | $66.90M |
| Dec 2008 | $43.05M | - |
FAQ
- What is Pacira BioSciences, Inc. annual total liabilities?
- What is the all-time high annual total liabilities for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. annual total liabilities year-on-year change?
- What is Pacira BioSciences, Inc. quarterly total liabilities?
- What is the all-time high quarterly total liabilities for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. quarterly total liabilities year-on-year change?
What is Pacira BioSciences, Inc. annual total liabilities?
The current annual total liabilities of PCRX is $775.17M
What is the all-time high annual total liabilities for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high annual total liabilities is $1.34B
What is Pacira BioSciences, Inc. annual total liabilities year-on-year change?
Over the past year, PCRX annual total liabilities has changed by +$70.91M (+10.07%)
What is Pacira BioSciences, Inc. quarterly total liabilities?
The current quarterly total liabilities of PCRX is $570.36M
What is the all-time high quarterly total liabilities for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high quarterly total liabilities is $1.34B
What is Pacira BioSciences, Inc. quarterly total liabilities year-on-year change?
Over the past year, PCRX quarterly total liabilities has changed by -$201.75M (-26.13%)